Alembic Pharmaceuticals gets USFDA approval for Dapsone Gel, 5%
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapsone Gel, 5%.
Dapsone Gel is indicated for the topical treatment of acne vulgaris.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Aczone Gel, 5%, of Almirall, LLC.
Alembic has a cumulative total of 244 ANDA approvals (224 final approvals and 20 tentative approvals) from USFDA.
The post Alembic Pharmaceuticals gets USFDA approval for Dapsone Gel, 5% appeared first on Express Pharma.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
Edusehat
Platform Edukasi Online Untuk Komunitas Kesehatan Agar Mendapatkan Informasi Dan Pengetahuan Terbaru Tentang Kesehatan Dari Nasional Maupun Internasional. ||
An online education platform for the health community to obtain the latest information and knowledge about health from both national and international sources.
